The pharmaceutical and life sciences industry is undergoing a tectonic shift, moving from static digital transformation to an era of "agentic labor." As artificial intelligence evolves from simple content generation to autonomous action, two industry titans—Salesforce and Veeva Systems—are locked in a high-stakes strategic battle.
At the recent Veeva Commercial Summit in Boston, the contrast between the two companies’ visions became starkly apparent. While Veeva, the long-standing incumbent in life sciences cloud software, touted its new "Falcon" platform, Salesforce took the opportunity to announce that over 140 life sciences organizations, including industry giants like Novartis, AstraZeneca, Moderna, and Merck Animal Health, have already deployed its Agentforce Life Sciences platform.
This is more than just a software upgrade; it represents a fundamental re-architecting of how global drug developers manage clinical trials, patient engagement, and commercial operations.
The Chronology of the Pivot: From CRM to Autonomous Agents
To understand the current rivalry, one must look back at the distinct paths both companies have taken toward AI maturity.
The Salesforce Path: A Decade of "AI-First" Ambition
Salesforce’s current dominance in the agentic space is the culmination of a decade-long strategy. In 2014, CEO Marc Benioff declared Salesforce an "AI-first company," a sentiment backed by the $390 million acquisition of RelateIQ. By 2016, the company introduced "Einstein," bringing predictive machine learning to the CRM.
However, the "Agentforce" brand, launched in September 2024, signaled a transition from passive analytics to autonomous "digital labor." With a public goal of empowering one billion agents by the end of 2025, Salesforce is betting that its scale—processing 28.6 trillion AI tokens in the first quarter of fiscal 2027 alone—will provide the data density necessary to outpace competitors.
The Veeva Response: Protecting the "Vault"
Veeva, meanwhile, built its reputation on deep, domain-specific compliance. Its response to the generative AI boom has been more measured, focusing on integrating "agentic labor" into its existing "Vault" ecosystem.
Following the launch of its Free Text and Voice agents in late 2025, Veeva accelerated its roadmap in 2026. The March 2026 acquisition of Ostro, an AI brand-engagement platform, for roughly $100 million, highlighted Veeva’s commitment to conversational AI that operates strictly within the guardrails of Medical, Legal, and Regulatory (MLR) approved content. The unveiling of the "Falcon" platform in May 2026 represents the company’s first cohesive attempt to unify these disparate agents into a standard framework for drug development.
Supporting Data: By the Numbers
The competition is quantifiable, both in adoption rates and infrastructure investment.
- Salesforce Scale: Joe Ferraro, SVP and GM of Life Sciences at Salesforce, notes that the 140-client milestone spans clinical, commercial, and patient engagement. The company reported $1.2 billion in annual recurring revenue (ARR) specifically from Agentforce as of mid-2026.
- The Token Surge: Salesforce’s AI token usage grew by 152% quarter-over-quarter, a metric the company uses to prove its platform’s stickiness and usage intensity.
- Veeva’s Integration: Veeva’s "Falcon" is slated for early-adopter availability in November 2026. Their strategy relies on the "Vault" ecosystem, which currently serves as the backbone for clinical, regulatory, and safety data for thousands of life sciences firms.
The Philosophical Divide: "Headless" vs. "Depth-Inside-App"
Perhaps the most significant differentiator between the two is their approach to architecture. Salesforce is pushing for a "headless" AI model, while Veeva remains committed to an in-context, application-centric approach.
Salesforce’s "Headless" Vision
Joe Ferraro describes the headless strategy as "popping the top off the platform." By exposing data models and workflows as Model Context Protocol (MCP) tools, Salesforce allows customers to run agentic tasks within third-party AI interfaces, such as Anthropic’s Claude.
The advantage here is flexibility. As Ferraro explains, "A customer who has made a significant investment in Anthropic can use our MCP service to bring all of those compliant workflows directly inside Claude." This approach acknowledges that customers may not want to live solely within a Salesforce UI; they want the power of Salesforce’s data and compliance engines accessible anywhere.
Veeva’s "Vault" Philosophy
Veeva takes the opposite stance. Its Vault AI Agents are designed to function exclusively within the Veeva environment. By keeping the agents "in-context" against the customer’s proprietary data and documents, Veeva aims to ensure higher security and lower hallucinations. While Salesforce embraces a "bring your own model" approach for Agentforce, Veeva fixes the model layer for its standard agents—relying on Amazon Bedrock (Anthropic and Amazon models)—to ensure predictability and regulatory adherence.
Official Perspectives: Ferraro vs. Gassner
The rivalry has moved beyond product features into the realm of corporate culture and speed.
Joe Ferraro of Salesforce does not mince words regarding the competition. When asked about Veeva’s recent moves, he suggested that "customer pressure really forced Veeva’s hand." Ferraro emphasizes the scale of Salesforce’s engineering team—numbering in the thousands—as a decisive factor. "There is nowhere near that scale for Veeva, so we are able to move a lot faster from an agentic standpoint," he claims.
Peter Gassner, CEO of Veeva Systems, focuses on the necessity of "agentic commercial models" in changing how pharma companies operate. Rather than focusing on "headless" flexibility, Gassner focuses on the "AI Tab," a conversational layer coming in August 2026 that allows users to query Vault data securely. His argument is that for life sciences, the context of the data is more important than the interface through which it is accessed.
Implications for the Life Sciences Industry
The shift toward agentic AI has profound implications for pharmaceutical companies.
1. Accelerated Onboarding and Reduced Consulting Dependency
One of the most immediate benefits is the speed of implementation. Salesforce reports that smaller life science customers are completing onboarding in roughly one month, down from traditional timelines that spanned several quarters. Agents are now performing configuration tasks—such as adding buttons to apps or updating UI workflows—that previously required expensive teams of consultants.
2. The Determinism Challenge
In a regulated industry, "probabilistic" AI is a liability. A model that hallucinates can result in severe legal and safety consequences. Both companies are addressing this through deterministic guardrails:
- Salesforce uses "Agent Script," which forces AI to follow approved templates and verify consent status before executing actions.
- Veeva relies on its existing Vault workflows, ensuring that the AI cannot "go off script" because the necessary tools are simply not available to it.
3. The End of the "One-Size-Fits-All" Platform
The industry is moving toward a future where the CRM is no longer just a database of records, but an active participant in decision-making. As these agents become more sophisticated, the role of the pharmaceutical representative, the clinical trial monitor, and the regulatory expert will likely transition from manual data entry to "agent oversight."
Conclusion: A New Era of Competition
As we head into late 2026, the battle between Salesforce and Veeva is a microcosm of the broader AI revolution. Salesforce is betting that openness, interoperability (via MCP), and raw engineering scale will win the day. Veeva is doubling down on its "moat"—the deep, trusted, and regulated environment of the Vault—arguing that in life sciences, safety and compliance are worth more than the freedom to "surface" AI anywhere.
For the pharmaceutical industry, the result is a rare win-win: faster innovation, more efficient operations, and a robust competition that forces both vendors to accelerate their development cycles. Whether the future is "headless" or "Vault-bound," one thing is clear: the era of the autonomous agent has officially arrived in the life sciences sector.
About the Author
